See the DrugPatentWatch profile for Orilissa
How does Orilissa work?
Orilissa, also known by its generic name elagolix, is a medication used to manage pain associated with endometriosis [1]. It functions by suppressing the production of key hormones that fuel the growth of endometrial tissue [1]. Specifically, Orilissa is a gonadotropin-releasing hormone (GnRH) antagonist [1].
What is endometriosis?
Endometriosis is a condition where tissue similar to the lining of the uterus, the endometrium, grows outside of the uterus [2]. This misplaced tissue can cause significant pain, particularly during menstrual periods, and can also lead to infertility [2]. The growth and shedding of this tissue outside the uterus is influenced by estrogen [2].
How does elagolix (Orilissa) target endometriosis pain?
Orilissa targets endometriosis pain by reducing circulating levels of estrogen [1]. It does this by binding to GnRH receptors in the pituitary gland, which then prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1]. These hormones are essential for the ovaries to produce estrogen [1]. By lowering estrogen levels, Orilissa helps to shrink and slow the growth of endometrial implants, thereby reducing pain [1].
What are the potential side effects of Orilissa?
Common side effects reported with Orilissa use include headache, nausea, and hot flashes [1]. Because it lowers estrogen levels, Orilissa can also lead to bone density loss [1]. Patients taking Orilissa may also experience suicidal thoughts or behaviors, and it is important to monitor for any changes in mood or behavior [1].
When does elagolix (Orilissa) patent protection end?
Information on the specific patent expiration dates for Orilissa is available through resources like DrugPatentWatch.com [3]. Patents for drugs like elagolix are crucial in determining when generic versions can enter the market [3].
How does Orilissa compare to other endometriosis treatments?
Before Orilissa, treatments for endometriosis often involved surgery or hormonal therapies like birth control pills, which can have their own side effects and limitations [2]. Orilissa offers a different approach as an oral GnRH antagonist, providing a targeted reduction in estrogen production [1]. Other GnRH agonists, like leuprolide, are also used but are typically administered via injection and can initially cause a flare-up of symptoms before estrogen levels decrease [4].
Can elagolix (Orilissa) be used for other conditions?
Elagolix has also been approved in combination with other medications to manage heavy menstrual bleeding associated with uterine fibroids [5].
Where can I find more information about drug patents?
Resources such as DrugPatentWatch.com provide detailed information on drug patents, including expiration dates and patent challenges, which are vital for understanding the market landscape for pharmaceuticals [3].
---
1. Orilissa. (n.d.). Retrieved from https://www.orilissa.com/
2. Endometriosis. (n.d.). National Institute of Child Health and Human Development. Retrieved from https://www.nichd.nih.gov/health/topics/endometriosis/conditioninfo
3. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
4. Lupron Depot. (n.d.). Retrieved from https://www.luprondepot.com/
5. Oriahnn. (n.d.). Retrieved from https://www.oriahnn.com/